<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2116">
  <stage>Registered</stage>
  <submitdate>25/09/2008</submitdate>
  <approvaldate>25/09/2008</approvaldate>
  <nctid>NCT00760877</nctid>
  <trial_identification>
    <studytitle>Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)</studytitle>
    <scientifictitle>An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2009-012616-40</secondaryid>
    <secondaryid>CAMN107A2405</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>CHRONIC MYELOGENOUS LEUKEMIA</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Nilotinib
Treatment: drugs - Imatinib

Experimental: Nilotinib - Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.

Active Comparator: Imatinib - Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.


Treatment: drugs: Nilotinib
Supplied in 200 mg capsules

Treatment: drugs: Imatinib
Supplied in 100 mg and 400 mg capsules

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rate of Confirmed Best Cumulative Complete Molecular Response (CMR) - The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the first 12 months of treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) = 0.00001 by real-time quantitative polymerase chain reaction (RQ-PCR) where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity &gt;4.5 logs.</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of Confirmed Best Cumulative CMR - The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the 24, 36 and 48 months post treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) = 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity &gt;4.5 logs.</outcome>
      <timepoint>24 months, 36 month, 48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Cross-over Participants With CMR - The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) = 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity &gt;4.5 logs.</outcome>
      <timepoint>24 months, 36 months, 48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival (PFS) - PFS was defined as the time from the date of randomization to the date of the earliest documented progression-defining event as follows: transformation to blast crisis or accelerated phase disease, or death from any cause.</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Event-free Survival - Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following events on study treatment: loss of complete hematological response, confirmed loss of complete cytogenetic response (CCyR), confirmed loss of major molecular response (MMR), death from any cause during treatment, progression to the accelerated phase or blast crisis of chronic myelogenous leukemia (CML) per European Leukemia Network (ELN) criteria, whichever was earliest.</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival - Overall survival was defined as the time from the date of randomization to the date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment.</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of chronic myeloid leukemia associated with BCR-ABL quantifiable by RQ-PCR
        Documented CCyR by bone marrow or BCR-ABL&lt;1% IS in the past 12 months Persistent disease
        demonstrated by two PCR positive tests 3 months apart both during the past 6 months.

        Treatment with imatinib for at least 2 years with 400 mg or 600 mg and a stable dose No
        other current or planned anti-leukemia therapies</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patient has evidence of rising PCR (a confirmed &gt;1 log increase in previous 6 months)
        Patient has received another investigational agent within last 6 months or tyrosine kinase
        inhibitors (TKIs) other than imatinib Prior allogeneic stem cell transplantation

        Impaired cardiac function including any one of the following:

        Inability to monitor the QT interval on electrocardiogram (ECG) Long QT syndrome or a known
        family history of long QT syndrome. Clinically significant resting brachycardia (&lt;50 beats
        per minute) QTc &gt; 450 msec on baseline ECG (using the QTcF formula). If QTcF &gt;450 msec and
        electrolytes are not within normal ranges, electrolytes should be corrected and then the
        patient re-screened for QTc Myocardial infarction within 12 months prior to starting study
        Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive
        heart failure or uncontrolled hypertension) History of or presence of clinically
        significant ventricular or atrial tachyarrhythmias Administration of cytokine therapy (e.g.
        G-CSF, GM-CSF or SCF) within 4 weeks prior to study entry</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>207</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Novartis Investigative Site - St. Leonards</hospital>
    <hospital>Novartis Investigative Site - Westmead</hospital>
    <hospital>Novartis Investigative Site - Herston</hospital>
    <hospital>Novartis Investigative Site - South Brisbane</hospital>
    <hospital>Novartis Investigative Site - Woolloongabba</hospital>
    <hospital>Novartis Investigative Site - Adelaide</hospital>
    <hospital>Novartis Investigative Site - Parkville</hospital>
    <hospital>Novartis Investigative Site - Prahran</hospital>
    <hospital>Novartis Investigative Site - Nedlands</hospital>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>3181 - Prahran</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>MG</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>PR</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RJ</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon cedex 04</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre les Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andalucia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalu√±a</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Navarra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary goal of this study was to determine the rate of confirmed best cumulative
      complete molecular response (CMR) within the first year of study therapy with imatinib or
      nilotinib. The study also explored the impact and significance of the achieved CMR on patient
      outcomes (progression free survival (PFS), event free survival (EFS) and overall survival
      (OS), characterized the kinetics of CMR achieved in both treatment arms and after the
      cross-over.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00760877</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>